Nagoya Protocol: ‘a masterpiece of ambiguity’

Since the Nagoya Protocol was implemented in October 2014, lawyers, academics, and the life sciences industry broadly have been calling upon institutions such as the European Union for guidance on how to best abide by the new regulations.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Careers

Winston & Strawn and Taylor Wessing UK seal ‘powerhouse’ merger

30 January 2026 Transatlantic ‘powerhouse’ Winston Taylor is set to launch in May 2026, with a particular focus on technology, life sciences and transatlantic services.

Careers

Pearce IP grows practice with senior patent hire

29 January 2026 Melbourne-based firm adds senior attorney with over 25 years of experience in therapeutics, diagnostics and biologics as demand for specialist patent services rises.

Americas

Sanofi suffers setback in insulin monopoly dispute

29 January 2026 A judge has allowed antitrust claims against the pharma giant to move forward, finding that it plausibly used bundled rebates and patent abuse to extend its insulin monopoly, though one allegation was dismissed.

More features

Winston & Strawn and Taylor Wessing UK seal ‘powerhouse’ merger

Pearce IP grows practice with senior patent hire

Sanofi suffers setback in insulin monopoly dispute

Firm adds seven-lawyer team in second major merger

Eli Lilly’s Mounjaro tops list of cyber squatter targets

The quantum advantage: IP considerations for the next generation of life sciences innovation

Fed Circ overturns PTAB decision in $83.4m DNA case

Simpson Thacher adds ‘exemplary’ litigator with emerging tech expertise

Nagoya Protocol: ‘a masterpiece of ambiguity’

More on this story

Editor's picks

Editor's picks

More features